Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease

Jau Jiuan Sheu, Li Yu Yang, Monika Renuka Sanotra, Sen Te Wang, Hsien Tsung Lu, Rachel Sook Yee Kam, I. Uen Hsu, Shu Huei Kao, Ching Kuo Lee, Jonathan Chang Cheng Shieh, Yung Feng Lin

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

Objective: The development of blood-based biomarkers for early diagnosis and treatment of Alzheimer's disease (AD) is desirable. In AD model mouse brain and neuronal cells, Abelson helper integration site-1 (AHI1) protein is reduced. AHI1 facilitates intracellular amyloid precursor protein (APP) translocation to inhibit amyloidogenic pathology of AD, and thus may be an AD biomarker. Methods: This study was conducted among 32 AD patients and 54 healthy control (HC) subjects. AHI1-related protein levels from initially collected serum samples in each group were screened using Western blotting. The protein concentrations of AHI1 and amyloid-β (Aβ), peptide(s) derived from APP, from all serum samples were analyzed using ELISA. Results: In AD serum, AHI1 and a large truncated C-terminal APP fragment were significantly reduced. The average concentrations of serum AHI1 and Aβ in AD were significantly lower than those in HC. Notably, AHI1 concentration in HC serum was decreased in an age-dependent manner, while it was consistently low in AD serum and had no correlation with Aβ or mini-mental state examination score. The receiver operating characteristic analysis on all subjects demonstrated an area under curve (AUC) value of 0.7 for AHI1 on AD diagnosis, while the AUC increased to 0.82 on the subjects younger than 77 years old, suggesting a good diagnostic performance of serum AHI1 for AD especially at relatively young age. Conclusion: An early event of AHI1 reduction in the body of AD patients was observed. Serum AHI1 may be valuable for early diagnosis of AD.
原文英語
期刊Clinical Biochemistry
DOIs
出版狀態接受/付印 - 一月 1 2019

指紋

Alzheimer Disease
Serum
Amyloid beta-Protein Precursor
Amyloid
Area Under Curve
Biomarkers
Early Diagnosis
Proteins
Protein Transport
Helper-Inducer T-Lymphocytes
ROC Curve
Pathology
Healthy Volunteers
Western Blotting
Enzyme-Linked Immunosorbent Assay
Brain
Blood
Peptides

ASJC Scopus subject areas

  • Clinical Biochemistry

引用此文

Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease. / Sheu, Jau Jiuan; Yang, Li Yu; Sanotra, Monika Renuka; Wang, Sen Te; Lu, Hsien Tsung; Kam, Rachel Sook Yee; Hsu, I. Uen; Kao, Shu Huei; Lee, Ching Kuo; Shieh, Jonathan Chang Cheng; Lin, Yung Feng.

於: Clinical Biochemistry, 01.01.2019.

研究成果: 雜誌貢獻文章

@article{33c64835216f4b9eb472808648fcf7f1,
title = "Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease",
abstract = "Objective: The development of blood-based biomarkers for early diagnosis and treatment of Alzheimer's disease (AD) is desirable. In AD model mouse brain and neuronal cells, Abelson helper integration site-1 (AHI1) protein is reduced. AHI1 facilitates intracellular amyloid precursor protein (APP) translocation to inhibit amyloidogenic pathology of AD, and thus may be an AD biomarker. Methods: This study was conducted among 32 AD patients and 54 healthy control (HC) subjects. AHI1-related protein levels from initially collected serum samples in each group were screened using Western blotting. The protein concentrations of AHI1 and amyloid-β (Aβ), peptide(s) derived from APP, from all serum samples were analyzed using ELISA. Results: In AD serum, AHI1 and a large truncated C-terminal APP fragment were significantly reduced. The average concentrations of serum AHI1 and Aβ in AD were significantly lower than those in HC. Notably, AHI1 concentration in HC serum was decreased in an age-dependent manner, while it was consistently low in AD serum and had no correlation with Aβ or mini-mental state examination score. The receiver operating characteristic analysis on all subjects demonstrated an area under curve (AUC) value of 0.7 for AHI1 on AD diagnosis, while the AUC increased to 0.82 on the subjects younger than 77 years old, suggesting a good diagnostic performance of serum AHI1 for AD especially at relatively young age. Conclusion: An early event of AHI1 reduction in the body of AD patients was observed. Serum AHI1 may be valuable for early diagnosis of AD.",
keywords = "Abelson helper integration site-1 (AHI1), Alzheimer's (Alzheimer) disease (AD), Amyloid precursor protein (APP), Amyloid-β (Aβ), Biomarker",
author = "Sheu, {Jau Jiuan} and Yang, {Li Yu} and Sanotra, {Monika Renuka} and Wang, {Sen Te} and Lu, {Hsien Tsung} and Kam, {Rachel Sook Yee} and Hsu, {I. Uen} and Kao, {Shu Huei} and Lee, {Ching Kuo} and Shieh, {Jonathan Chang Cheng} and Lin, {Yung Feng}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2019.11.011",
language = "English",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease

AU - Sheu, Jau Jiuan

AU - Yang, Li Yu

AU - Sanotra, Monika Renuka

AU - Wang, Sen Te

AU - Lu, Hsien Tsung

AU - Kam, Rachel Sook Yee

AU - Hsu, I. Uen

AU - Kao, Shu Huei

AU - Lee, Ching Kuo

AU - Shieh, Jonathan Chang Cheng

AU - Lin, Yung Feng

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: The development of blood-based biomarkers for early diagnosis and treatment of Alzheimer's disease (AD) is desirable. In AD model mouse brain and neuronal cells, Abelson helper integration site-1 (AHI1) protein is reduced. AHI1 facilitates intracellular amyloid precursor protein (APP) translocation to inhibit amyloidogenic pathology of AD, and thus may be an AD biomarker. Methods: This study was conducted among 32 AD patients and 54 healthy control (HC) subjects. AHI1-related protein levels from initially collected serum samples in each group were screened using Western blotting. The protein concentrations of AHI1 and amyloid-β (Aβ), peptide(s) derived from APP, from all serum samples were analyzed using ELISA. Results: In AD serum, AHI1 and a large truncated C-terminal APP fragment were significantly reduced. The average concentrations of serum AHI1 and Aβ in AD were significantly lower than those in HC. Notably, AHI1 concentration in HC serum was decreased in an age-dependent manner, while it was consistently low in AD serum and had no correlation with Aβ or mini-mental state examination score. The receiver operating characteristic analysis on all subjects demonstrated an area under curve (AUC) value of 0.7 for AHI1 on AD diagnosis, while the AUC increased to 0.82 on the subjects younger than 77 years old, suggesting a good diagnostic performance of serum AHI1 for AD especially at relatively young age. Conclusion: An early event of AHI1 reduction in the body of AD patients was observed. Serum AHI1 may be valuable for early diagnosis of AD.

AB - Objective: The development of blood-based biomarkers for early diagnosis and treatment of Alzheimer's disease (AD) is desirable. In AD model mouse brain and neuronal cells, Abelson helper integration site-1 (AHI1) protein is reduced. AHI1 facilitates intracellular amyloid precursor protein (APP) translocation to inhibit amyloidogenic pathology of AD, and thus may be an AD biomarker. Methods: This study was conducted among 32 AD patients and 54 healthy control (HC) subjects. AHI1-related protein levels from initially collected serum samples in each group were screened using Western blotting. The protein concentrations of AHI1 and amyloid-β (Aβ), peptide(s) derived from APP, from all serum samples were analyzed using ELISA. Results: In AD serum, AHI1 and a large truncated C-terminal APP fragment were significantly reduced. The average concentrations of serum AHI1 and Aβ in AD were significantly lower than those in HC. Notably, AHI1 concentration in HC serum was decreased in an age-dependent manner, while it was consistently low in AD serum and had no correlation with Aβ or mini-mental state examination score. The receiver operating characteristic analysis on all subjects demonstrated an area under curve (AUC) value of 0.7 for AHI1 on AD diagnosis, while the AUC increased to 0.82 on the subjects younger than 77 years old, suggesting a good diagnostic performance of serum AHI1 for AD especially at relatively young age. Conclusion: An early event of AHI1 reduction in the body of AD patients was observed. Serum AHI1 may be valuable for early diagnosis of AD.

KW - Abelson helper integration site-1 (AHI1)

KW - Alzheimer's (Alzheimer) disease (AD)

KW - Amyloid precursor protein (APP)

KW - Amyloid-β (Aβ)

KW - Biomarker

UR - http://www.scopus.com/inward/record.url?scp=85076863044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076863044&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2019.11.011

DO - 10.1016/j.clinbiochem.2019.11.011

M3 - Article

C2 - 31786207

AN - SCOPUS:85076863044

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -